New Antibody-Drug conjugate takes aim at Hard-to-Treat leukemia
NCT ID NCT06359002
First seen Jan 28, 2026 · Last updated May 23, 2026 · Updated 14 times
Summary
This early-stage trial tests a new drug called BYON4413 in 16 people whose acute myeloid leukemia (AML) or myelodysplastic neoplasms (MDS) have returned or not responded to standard treatments. The drug is an antibody-drug conjugate designed to deliver a toxic payload directly to cancer cells. The main goals are to check safety and find the right dose, while also looking for signs that the drug can shrink or eliminate the cancer.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED/REFRACTORY AML are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Het Ziekenhuisnetwerk Antwerpen
Antwerp, Belgium
-
Hospital Clinic de Barcelona
Barcelona, Spain
-
Hospital San Pedro de Alcantara
Cáceres, Spain
-
Hospital Universitario de Salamanca
Salamanca, Spain
-
Hospital Universitario y Politecnico La Fe
Valencia, Spain
-
Hospital de la Santa Creu i Sant Pau
Barcelona, Spain
-
Institut Catala d'Oncologia
Badalona, Spain
-
UZ Leuven
Leuven, Belgium
-
Universitair Medisch Centrum Groningen
Groningen, Netherlands
Conditions
Explore the condition pages connected to this study.